Effect of Acute Antipsychotic Administration on Dopamine Synthesis in Rodents and Human Subjects Using 6-[18F]-L-m-tyrosine

Synapse

Volumn 52, Issue 2, 2004, Pages 153-162

  Mamo, David ^a,b   Remington, Gary ^a,b   Nobrega, Jose ^a,b   Hussey, Doug ^b   Chirakal, Raman ^c   Wilson, Alan A ^a,b   Baker, Glen ^d   Houle, Sylvain ^a,b   Kapur, Shitij ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^c Hamilton Health Sciences Hamilton ^*  (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

Author keywords

6 18F L m tyrosine; Antipsychotics; Aromatic amino acid decarboxylase; Dopamine synthesis; Positron emission tomography

Indexed keywords

AROMATIC LEVO AMINO ACID DECARBOXYLASE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; FLUORINE 18; HALOPERIDOL; NEUROLEPTIC AGENT; RISPERIDONE; TYROSINE;

ACUTE DRUG ADMINISTRATION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CEREBELLUM; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOPAMINE METABOLISM; DRUG EFFECT; ENZYME ACTIVITY; EX VIVO STUDY; IN VIVO STUDY; METABOLITE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOACTIVITY; RAT; RODENT;

ADULT; ANIMALS; ANTIPSYCHOTIC AGENTS; AROMATIC-L-AMINO-ACID DECARBOXYLASES; CORPUS STRIATUM; DOPAMINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; MALE; RATS; RATS, SPRAGUE-DAWLEY; TOMOGRAPHY, EMISSION-COMPUTED; TYROSINE;

EID: 1842614887     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/syn.20016     Document Type: Article

References (61)

1. Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS, Weiss R, Cooper TB, Mann JJ, Van Heertum RL, Gorman JM, Laruelle M. 2000. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci USA 97:8104-8109.
2. Anden NE, Roos BE, Werdinius B. 1964. Effects of chlorpromazine, haloperidol and reserpine on the levels of phenolic acids in rabbit corpus striatum. Life Sci 3:149-158.
3. Anden NE, Corrodi H, Fuxe K, Ungerstedt U. 1971. Importance of nervous impulse flow for the neuroleptic induced increase in amine turnover in central dopamine neurons. Eur J Pharmacol 15:193-199.
4. Anden NE, Corrodi H, Fuxe K. 1972. Effect of neuroleptic drugs on central catecholamine turnover assessed using tyrosine- and dopamine-hydroxylase inhibitors. J Pharm Pharmacol 24:177-182.
5. Andreasen NC, O'Leary DS, Flaum M, Nopoulos P, Watkins GL, Boles Ponto LL, Hichwa RD. 1997. Hypofrontality in schizophrenia: distributed dysfunctional circuits in neuroleptic-naive patients. Lancet 349:1730-1734.
6. Asselin MC AS, Chirakal R, Thompson M, Nahmias C. 2002. Brain imaging using PET. Patterns of distribution of [18F]6-Fluoro-L-m-tyrosine in PET images of patients with movement disorders. In: Senda M, Kimura Y, Herscovitch P, editors. Brain imaging using PET. San Diego: Academic Press.
7. Baker GB, Coutts RT, Rao TS. 1987. Neuropharmacological and neurochemical properties of N-(2-cyanoethyl)-2-phenylethylamine, a prodrug of 2-phenylethylamine. Br J Pharmacol 92:243-255.
8. Bankiewicz KS, Eberling JL, Kohutnicka M, Jagust W, Pivirotto P, Bringas J, Cunningham J, Budinger TF, Harvey-White J. 2000. Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp Neurol 164:2-14.
9. Barrio JR, Huang SC, Yu DC, Melega WP, Quintana J, Cherry SR, Jacobson A, Namavari M, Satyamurthy N, Phelps ME. 1996. Radiofluorinated L-m-tyrosines: new in-vivo probes for central dopamine biochemistry. J Cereb Blood Flow Metab 16:667-678.
10. Bartlett EJ, Brodie JD, Simkowitz P, Dewey SL, Rusinek H, Wolf AP, Fowler JS, Volkow ND, Smith G, Wolkin A. 1994. Effects of haloperidol challenge on regional cerebral glucose utilization in normal human subjects. Am J Psychiatry 151:681-686.
11. Bartlett EJ, Brodie JD, Simkowitz P, Dewey SL, Rusinek H, Volkow ND, Wolf AP, Smith G, Wolkin A, Cancro R. 1996. Time-dependent effects of a haloperidol challenge on energy metabolism in the normal human brain. Psychiatry Res 60:91-99.
12. Brown WD, DeJesus OT, Pyzalski RW, Malischke L, Roberts AD, Shelton SE, Uno H, Houser WD, Nickles RJ, Holden JE. 1999. Localization of trapping of 6-[(18)F]fluoro-L-m-tyrosine, an aromatic L-amino acid decarboxylase tracer for PET. Synapse 34:111-123.
13. Bunney BS, Walters JR, Roth RH, Aghajanian GK. 1973. Dopaminergic neurons: effect of antipsychotic drugs and amphetamine on single cell activity. J Pharmacol Exp Ther 185:560-571.
14. Carlsson A, Lindqvist, M. 1963. Effect of chlorpromazine and haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharm Toxicol 20:140-144.
15. Cho S, Neff NH, Hadjiconstantinou M. 1997. Regulation of tyrosine hydroxylase and aromatic L-amino acid decarboxylase by dopaminergic drugs. Eur J Pharmacol 323:149-157.
16. Cumming P, Gjedde A. 1998. Compartmental analysis of dopa decarboxylation in living brain from dynamic positron emission tomograms. Synapse 29:37-61.
17. Cumming P, Kuwabara H, Ase A, Gjedde A. 1995. Regulation of DOPA decarboxylase activity in brain of living rat. J Neurochem 65:1381-1390.
18. Cumming P, Ase A, Laliberte C, Kuwabara H, Gjedde A. 1997a. In vivo regulation of DOPA decarboxylase by dopamine receptors in rat brain. J Cereb Blood Flow Metab 17:1254-1260.
19. Cumming P, Deep P, Rousset O, Evans A, Gjedde A. 1997b. On the rate of decarboxylation of dopa to dopamine in living mammalian brain. Ann NY Acad Sci 835:274-308.
20. Da Prada M, Pletscher A. 1966. On the mechanism of chlorpromazine-induced changes of cerebral homovanillic acid levels. J Pharm Pharmacol 18:628-630.
21. Danielsen EH, Smith D, Hermansen F, Gjedde A, Cumming P. 2001. Acute neuroleptic stimulates DOPA decarboxylase in porcine brain in vivo. Synapse 41:172-175.
22. Dawson LA, Raley JM, de la Flor R, Shilliam CS. 2003. Temporal changes in 5-HT and DA turnover following acute and chronic treatment with typical and atypical antipsychotics. Schiz Res 60:105.
23. DeJesus OT, Sunderland JJ, Nickles JR, Mukherjee J, Appelman EH. 1990a. Synthesis of radiofluorinated analogs of m-tyrosine as potential L-dopa tracers via direct reaction with acetylhypofluorite. Int J Rad Appl Instrum [A] 41:433-437.
24. DeJesus OT, Sunderland JJ, Nickles R. 1990b. Synthesis of 18F-6-FD. J Nucl Med 31:2076-2077.
25. DeJesus OT, Endres CJ, Shelton SE, Nickles RJ, Holden JE. 1997. Evaluation of fluorinated m-tyrosine analogs as PET imaging agents of dopamine nerve terminals: comparison with 6-fluoro-DOPA. J Nucl Med 38:630-636.
26. Delay J DP, Harl J. 1952. Traitment des etats d'excitation et d'agitation par une methode medicamentense derivee de l'hibernotherapie. Ann Med Psychol 267-273.
27. Doudet DJ, Chan GL, Jivan S, DeJesus OT, McGeer EG, English C, Ruth TJ, Holden JE. 1999. Evaluation of dopaminergic presynaptic integrity: 6-[18F]fluoro-L-dopa versus 6-[18F]fluoro-L-m-tyrosine. J Cereb Blood Flow Metab 19:278-287.
28. Endres CJ, Swaminathan S, DeJesus OT, Sievert M, Ruoho AE, Murali D, Rommelfanger SG, Holden JE. 1997. Affinities of dopamine analogs for monoamine granular and plasma membrane transporters: implications for PET dopamine studies. Life Sci 60:2399-2406.
29. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G. 1992. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 49:538-544.
30. Gjedde A. 1996. DOPA decarboxylase. Mov Disord 11:462-463.
31. Grimm JW, See RE. 1998. Unique activation of extracellular striatopallidal neurotransmitters in rats following acute risperidone. Brain Res 801:182-189.
32. Grunder G, Vernaleken I, Muller MJ, Davids E, Heydari N, Buchholz HG, Bartenstein P, Munk OL, Stoeter P, Wong DF, Gjedde A, Cumming P. 2003. Subchronic haloperidol downregulates dopamine synthesis capacity in the brain of schizophrenic patients in vivo. Neuropsychopharmacology 28:787-794.
33. Hadjiconstantinou M, Wemlinger TA, Sylvia CP, Hubble JP, Neff NH. 1993. Aromatic L-amino acid decarboxylase activity of mouse striatum is modulated via dopamine receptors. J Neurochem 60:2175-2180.
34. Holden JE, Doudet D, Endres CJ, Chan GL, Morrison KS, Vingerhoets FJ, Snow BJ, Pate BD, Sossi V, Buckley KR, Ruth TJ. 1997. Graphical analysis of 6-fluoro-L-dopa trapping: effect of inhibition of catechol-O-methyltransferase. J Nucl Med 38:1568-1574.
35. Jordan S, Eberling JL, Bankiewicz KS, Rosenberg D, Coxson PG, VanBrocklin HF, O'Neil JP, Emborg ME, Jagust WJ. 1997. 6-[18F]fluoro-L-m-tyrosine: metabolism, positron emission tomography kinetics, and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine lesions in primates. Brain Res 750:264-276.
36. Kapur S, Remington G. 2001. Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry 50:873-883.
37. Kapur S, Zipursky RB, Remington G. 1999. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 156:286-293.
38. Kapur S, Wadenberg ML, Remington G. 2000a. Are animal studies of antipsychotics appropriately dosed? Lessons from the bedside to the bench. Can J Psychiatry 45:241-246.
39. Kapur S, Zipursky R, Jones C, Remington G, Houle S. 2000b. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 157:514-520.
40. Kapur S, VanderSpek SC, Brownlee BA, Nobrega JN. 2003. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J Pharmacol Exp Ther 305:625-631.
41. Laverty R, Sharman DF. 1965. Modification by drugs of the metabolism of 3,4-dihydroxyphenylethylamine, noradrenaline and 5-hydroxytryptamine in the brain. Br J Pharmacol 24:759-772.
42. Melega WP, Perlmutter MM, Luxen A, Nissenson CH, Grafton ST, Huang SC, Phelps ME, Barrio JR. 1989. 4-[18F]Fluoro-L-m-tyrosine: an L-3,4-dihydroxyphenylalanine analog for probing presynaptic dopaminergic function with positron emission tomography. J Neurochem 53:311-314.
43. Miller DD, Rezai K, Alliger R, Andreasen NC. 1997. The effect of antipsychotic medication on relative cerebral blood perfusion in schizophrenia: assessment with technetium-99m hexamethyl-propyleneamine oxime single photon emission computed tomography. Biol Psychiatry 41:550-559.
44. Miller DD, Andreasen NC, O'Leary DS, Watkins GL, Boles Ponto LL, Hichwa RD. 2001. Comparison of the effects of risperidone and haloperidol on regional cerebral blood flow in schizophrenia. Biol Psychiatry 49:704-715.
45. Nahmias C, Wahl L, Chirakal R, Firnau G, Garnett ES. 1995. A probe for intracerebral aromatic amino-acid decarboxylase activity: distribution and kinetics of [18F]6-fluoro-L-m-tyrosine in the human brain. Mov Disord 10:298-304.
46. Ngan ET, Lane CJ, Ruth TJ, Liddle PF. 2002. Immediate and delayed effects of risperidone on cerebral metabolism in neuroleptic naive schizophrenic patients: correlations with symptom change. J Neurol Neurosurg Psychiatry 72:106-110.
47. Nissbrandt H, Sundstrom E, Jonsson G, Hjorth S, Carlsson A. 1989. Synthesis and release of dopamine in rat brain: comparison between substantia nigra pars compacts, pars reticulata, and striatum. J Neurochem 52:1170-1182.
48. Nordstrom AL, Farde L, Wiesel FA, Forslund K, Pauli S, Halldin C, Uppfeldt G. 1993. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry 33:227-235.
49. Nyback H, Sedvall G. 1968. Effect of chlorpromazine on accumulation and disappearance of catecholamines formed from tyrosine-C14 in brain. J Pharmacol Exp Ther 162:294-301.
50. O'Keeffe R, Sharman DF, Vogt M. 1970. Effect of drugs used in psychoses on cerebral dopamine metabolism. Br J Pharmacol 38:287-304.
51. Patlak CS, Blasberg RG. 1985. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab 5:584-590.
52. Porrino LJ. 1993. Functional consequences of acute cocaine treatment depend on route of administration. Psychopharmacology (Berl) 112:343-351.
53. Stout DB, Huang SC, Melega WP, Raleigh MJ, Phelps ME, Barrio JR. 1998. Effects of large neutral amino acid concentrations on 6-[F18]Fluoro-L-DOPA kinetics. J Cereb Blood Flow Metab 18:43-51.
54. Tauscher J, Jones C, Remington G, Zipursky RB, Kapur S. 2002. Significant dissociation of brain and plasma kinetics with antipsychotics. Mol Psychiatry 7:317-321.
55. Torstenson R, Hartvig P, Langstrom B, Bastami S, Antoni G, Tedroff J. 1998. Effect of apomorphine infusion on dopamine synthesis rate relates to dopaminergic tone. Neuropharmacology 37:989-995.
56. Volkow ND, Wang GJ, Fischman MW, Foltin R, Fowler JS, Franceschi D, Franceschi M, Logan J, Gatley SJ, Wong C, Ding YS, Hitzemann R, Pappas N. 2000. Effects of route of administration on cocaine induced dopamine transporter blockade in the human brain. Life Sci 67:1507-1515.
57. Wahl LM, Chen JJ, Thompson M, Chirakal R, Nahmias C. 1999. The time course of metabolites in human plasma after 6-[(18)F]fluoro-l-m-tyrosine administration. Eur J Nucl Med 26:1407-1412.
58. Wolkin A, Barouche F, Wolf AP, Rotrosen J, Fowler JS, Shiue CY, Cooper TB, Brodie JD. 1989. Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia. Am J Psychiatry 146:905-908.
59. Zhu MY, Juorio AV, Paterson IA, Boulton AA. 1992. Regulation of aromatic L-amino acid decarboxylase by dopamine receptors in the rat brain. J Neurochem 58:636-641.
60. Zhu MY, Juorio AV, Paterson IA, Boulton AA. 1993. Regulation of striatal aromatic L-amino acid decarboxylase: effects of blockade or activation of dopamine receptors. Eur J Pharmacol 238:157-164.
61. Zhu MY, Juorio AV, Paterson IA, Boulton AA. 1994. Regulation of aromatic L-amino acid decarboxylase in rat striatal synaptosomes: effects of dopamine receptor agonists and antagonists. Br J Pharmacol 112:23-30.